Whiteley Joseph, Abrahmsén-Alami Susanna, Booth Jonathan, Mellor Steve, Humphrey James, Waters Laura J
School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, U.K.
Sustainable Innovation & Transformational Excellence, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg SE-431 83, Sweden.
Mol Pharm. 2025 Jun 2;22(6):3189-3197. doi: 10.1021/acs.molpharmaceut.5c00119. Epub 2025 Apr 30.
Coformulation is an approach to formulating multiple biopharmaceutical therapeutics in a single formulation, promising the benefits of both therapies in one dose. However, as molecular stability is a key consideration in traditional biopharmaceutical formulations, stability of coformulations will require extensive investigation. This study evaluated the effects of traditional formulation stabilizers, specifically surfactants, at different grades, namely, regular grade (RG) Tween 20 and Tween 80 and Super-refined Polysorbate 20 and 80. Their effects were assessed through their interactions with human serum albumin (HSA) and a glucagon-like peptide-1 (GLP-1) receptor agonist (MEDI7219). Isothermal titration calorimetry (ITC) and differential scanning calorimetry (DSC) were implemented to determine the strength of the binding interactions and thermal stability of the tertiary system. ITC confirmed that upon titration of MEDI7219 into a solution of HSA and RG, Tween 20 the binding affinity of the peptide was reduced, resulting in negatively cooperative binding. However, when the peptide was titrated into a solution of HSA and both grades of Tween 80, the binding affinity increased with positive cooperative binding. DSC established that MEDI7219 increased the thermal stability of HSA to a similar extent to the polysorbates. Combining peptide and polysorbate did not further increase the thermal stability of HSA; however, it did reduce the unfolding of HSA molecules in the absence of heat. Overall, the unique findings in this study have demonstrated that the order of addition in a ternary coformulation affects the final composition which is an important consideration for pharmaceutical development.
共配制是一种在单一制剂中配制多种生物制药疗法的方法,有望在一剂中实现两种疗法的益处。然而,由于分子稳定性是传统生物制药制剂中的关键考虑因素,共配制制剂的稳定性需要进行广泛研究。本研究评估了不同等级的传统制剂稳定剂,特别是表面活性剂,即常规级(RG)吐温20和吐温80以及超级精制聚山梨醇酯20和80的效果。通过它们与人类血清白蛋白(HSA)和胰高血糖素样肽-1(GLP-1)受体激动剂(MEDI7219)的相互作用来评估它们的效果。采用等温滴定量热法(ITC)和差示扫描量热法(DSC)来确定三元体系的结合相互作用强度和热稳定性。ITC证实,将MEDI7219滴定到HSA和RG吐温20的溶液中时,肽的结合亲和力降低,导致负协同结合。然而,当将肽滴定到HSA和两种等级吐温80的溶液中时,结合亲和力随着正协同结合而增加。DSC确定MEDI7219将HSA的热稳定性提高到与聚山梨醇酯相似的程度。将肽和聚山梨醇酯结合并没有进一步提高HSA的热稳定性;然而,它确实减少了在无热情况下HSA分子的解折叠。总体而言,本研究中的独特发现表明,三元共配制中的添加顺序会影响最终组成,这是药物开发中的一个重要考虑因素。